Company Profile

Chronix Biomedical Corporation
Profile last edited on: 2/21/18      CAGE: 41HS5      UEI:

Business Identifier: Molecular diagnostics: blood tests for monitoring minimal residual disease in cancer patients
Year Founded
1997
First Award
2006
Latest Award
2006
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

5941 Optical Court Suite 203E
San Jose, CA 95138
   (408) 960-2306
   info@chronixbiomedical.com
   www.chronixbiomedical.com
Location: Multiple
Congr. District: 19
County: Santa Clara

Public Profile

Chronix Biomedical Corporation is pioneering a breakthrough approach to the diagnosis and management of chronic diseases and cancer. A molecular diagnostic company, Chronix provides sequencing services to clinicians, universities, industry, and government agencies for breast cancer, prostate cancer, colorectal cancer, brain injuries and concussions, bovine spongiform encephalopathy (mad cow disease), and chronic fatigue syndrome. The firm has developed proprietary technology that measures and categorizes circulating nucleic acids, DNA sequences circulating in the blood that are associated with specific changes in disease and health status. Chronix plans to collaborate with a variety of partners to develop and market its DNA-based assays that have the potential to transform the management of a broad range of cancers and other conditions. Chronix is headquartered in San Jose, CA with research facilities in Germany.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
10-14
Revenue Range
1M-1.5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
5-9

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2006 1 OSD $99,966
Project Title: Development of novel methods and reagents for prion infection

Key People / Management

  Howard B Urnovitz -- Chief Executive Officer/Chief Science Officer and Co-Founder

  John Dipietro -- Founder, Chief Financial Officer and Senior VPof Finance & Administ

  Ekkehard Schutz -- Founder and Chief Technology Officer